PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION

International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International patent classification[7]: C07D 409/10, A61K 31/415	A1	(11) International publication number:	WO 00/68226
		(43) International publication date:	16 November 2000 (16.11.00)

(21) International application number: PCT/EP00/03891

(22) International filing date: 29 April 2000 (29.04.00)

(30) Data relating to the priority:
199 20 815.8 5 May 1999 (05.05.99) DE
199 61 686.8 21 December 1999 (21.12.99) DE

(71) Applicant: AVENTIS PHARMA DEUTSCHLAND GMBH [DE/DE]; Brüningstrasse 50, D-65929 Frankfurt (DE).

(72) Inventor: HEITSCH, Holger; Castellumstrasse 52,
(73) D-55252 Mainz-Kastel (DE). WIEMER, Gabriele; Ernst-Moritz-Arndt 21, D-61476 Kronberg (DE).


(81) Designated states: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO Patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
With the International Search Report.
Before expiry of the period provided for amending the claims, will be republished if such amendments are received.

As printed

(54) Title: 1-(P-THIENYLBENZYL)-IMIDAZOLES AS ANGIOTENSIN-(1-7) RECEPTOR AGONISTS, METHOD FOR THE PRODUCTION AND THE UTILIZATION THEREOF AND PHARMACEUTICAL PREPARATIONS CONTAINING SAID COMPOUNDS

(54) Bezeichnung: 1-(P-THIENYLBENZYL)-IMIDAZOLE ALS AGONISTEN VON ANGIOTENSIN-(1-7)-REZEPTOREN, VERFAHREN ZU IHRER HERSTELLUNG, IHRE VERWENDUNG UND SIE ENTHALTENDE PHARMAZEUTISCHE PRÄPARATE



(I)

(57) Abstract

The invention relates to novel 1-(p-thienylbenzyl)-imidazoles of formula (I), wherein radicals R(1)-R(6), X and Y have the meaning cited in the description. Said compounds are potent agonists of angiotensin-(1-7) receptors. As a result of the production and release of vasodilating, antithrombotic and cardioprotective messengers such as cyclic 3',5'-guanosine monophosphate (cGMP) and nitrogen monoxide (NO) associated with the stimulation of said receptors in the endothelial cells, said compounds represent valuable medicaments in the treatment and prophylaxis of hypertension, heart hypertrophy, heart failure, coronary heart diseases such as Angina Pectoris, myocardial infarct, vascular restenosis following angioplasty, cardiomyopathy, endothelial dysfunction or endothelial lesions, e.g. as a result of atherosclerotic processes or in case of Diabetis mellitus and arterial or venous thrombosis.

(57) Zusammenfassung

Die Erfindung betrifft neue 1–(p–Thienylbenzyl)–Imidazole der Formel (I), wobei die Reste R(1) bis R(6), X und Y die in der Beschreibung angegebene Bedeutung haben, die potente Agonisten von Angiotensin–(1–7)–Rezeptoren sind und durch die mit der Stimulation dieser Rezeptoren an Endothelzellen verbundene Produktion und Freisetzung der vasorelaxierenden, antithrombotischen und kardioprotektiven Botenstoffe cyclisches 3',5'–Guanosinmonophosphat (cGMP) und Stickstoffmonoxid (NO) wertvolle Arzneimittel zur Behandlung und Prophylaxe von Bluthochdruck, Herzhypertrophie, Herzinsuffizienz, koronaren Herzerkrankungen wie der Angina Pectoris, Herzinfarkt, vaskulärer Restenose nach Angioplastie, Kardiomyopathien, einer endothelialen Dysfunktion bzw. endothelialer Schädigungen, z.B. als Folge atheriosklerotischer Prozesse oder beim Diabetis mellitus, sowie von arterieller und venöser Thrombose darstellen.

ONLY FOR INFORMATION

Codes used to identify the PCT member States on the flyleaves of the brochures in which international applications made under the PCT are published.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaidjan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia-Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	Former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Fasso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Vietnam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrghyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Ivory Coast	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakhstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		